Welcome to our dedicated page for Fennec Pharmaceuticals news (Ticker: FENC), a resource for investors and traders seeking the latest updates and insights on Fennec Pharmaceuticals stock.
Fennec Pharmaceuticals Inc. reports developments as a commercial-stage specialty pharmaceutical company focused on PEDMARK® (sodium thiosulfate injection), a therapy used to reduce the risk of cisplatin-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors. The company also markets the product in Europe and the United Kingdom under the PEDMARQSI® name and has disclosed a licensing arrangement for commercialization in additional non-U.S. markets.
Recurring news themes include PEDMARK product sales and financial results, commercialization updates, scientific abstracts, investigator-sponsored and real-world studies in cancer patients receiving cisplatin-based chemotherapy, product exclusivity and patent matters, and equity compensation actions under Nasdaq rules.
Fennec Pharmaceuticals (NASDAQ:FENC) reported Q1 2026 net revenues of $15.1 million, a 73% year-over-year increase, driven by broader PEDMARK sales, including new AYA accounts. Net income was $0.2 million (EPS $0.01) versus a $1.2 million loss in Q1 2025. Cash and equivalents rose to $40.1 million.
Selling and marketing expenses increased to $11.4 million while G&A declined to $3.2 million. Fennec initiated a third institution-led PEDMARK study in AYA and adult head and neck and testicular cancers, and four PEDMARK abstracts will appear at the 2026 ASCO Annual Meeting.
Fennec Pharmaceuticals (NASDAQ: FENC) will release Q1 2026 financial results before U.S. market open on Thursday, May 14, 2026. Management will host a conference call and live webcast at 8:30 a.m. ET. A replay will be archived on the company website for 30 days.
Fennec Pharmaceuticals (NASDAQ: FENC) announced four abstracts evaluating PEDMARK® (sodium thiosulfate) were accepted to the 2026 ASCO Annual Meeting, May 29–June 2, 2026, in Chicago. Two items are poster presentations and two are abstract-only publications.
PEDMARK is approved for pediatric patients one month and older and carries a NCCN 2A recommendation for adolescent and young adult patients. Full abstracts will be available on the ASCO website on May 21, 2026 at 5:00 p.m. ET.
Fennec Pharmaceuticals (NASDAQ:FENC) announced the University of Arizona Cancer Center will conduct an investigator-sponsored Phase I/II study evaluating PEDMARK® (sodium thiosulfate) as an otoprotectant in adolescent/young adult and adult patients with head and neck and testicular cancers receiving cisplatin.
The release notes PEDMARK® is approved for pediatric patients one month and older and holds a NCCN 2A recommendation for AYA patients. Fennec cited two other recent institution-led studies at Tampa General Hospital and City of Hope; additional investigator-initiated studies are under review.
Fennec Pharmaceuticals (NASDAQ:FENC) announced inducement grants under Nasdaq Listing Rule 5635(c)(4). On March 31, 2026 the company granted incentive stock options to 24 new non-executive employees covering 377,500 shares under its 2026 Equity Inducement Plan.
All ISOs carry an exercise price of $5.77 (closing price on March 30, 2026), a 10-year term, and vest one-third after one year then monthly over the next 24 months, subject to continued employment.
Fennec Pharmaceuticals (NASDAQ: FENC) reported FY2025 net product sales of $44.6M (up 50% YoY) and Q4 2025 net product sales of $13.8M (up 75% YoY). Cash was $36.8M at year-end after oversubscribed $42M equity offerings and a $21.5M debt paydown, leaving $0 debt outstanding. The company reported a FY2025 net loss of $10.1M and continues to expand PEDMARK adoption, investigator-led studies, and real-world data generation.
Fennec Pharmaceuticals (NASDAQ: FENC) will release full year and fourth quarter 2025 financial results before U.S. markets open on March 24, 2026.
Management will host an 8:30 a.m. ET conference call and webcast the same day; a replay will be archived on the company website for 30 days.
Fennec Pharmaceuticals (NASDAQ:FENC) announced a settlement with Cipla resolving PEDMARK patent litigation. The lawsuit will be dismissed and Cipla agrees not to market a generic sodium thiosulfate product until September 1, 2033, subject to earlier entry under certain circumstances. PEDMARK is FDA‑approved to reduce cisplatin‑related ototoxicity in pediatric patients ≥1 month; pivotal Phase 3 data and safety rates are summarized in prescribing information.
Fennec Pharmaceuticals (NASDAQ:FENC) announced a clinical research collaboration with Tampa General Hospital Cancer Institute to evaluate real-world use of sodium thiosulfate injection (PEDMARK®) for reducing cisplatin-related ototoxicity in adolescent, young adult (AYA) and adult patients with non-metastatic solid tumors.
The study will analyze clinical and audiology monitoring data; PEDMARK is approved for pediatric patients aged one month and older and has a NCCN 2A recommendation for AYA patients.
Fennec Pharmaceuticals (NASDAQ:FENC) presented multi-institutional real-world data on PEDMARK® for adults with head & neck cancers at MHNCS, Feb 19–21, 2026. A retrospective review of 15 adults found PEDMARK® given ≥6 hours after cisplatin was safely integrated into care with no disruption to curative-intent cisplatin delivery.
Most high-risk patients showed no measurable hearing loss during or after treatment, PEDMARK® had only isolated, self-limited infusion events and no grade 3–4 toxicities, supporting further exploration in head & neck cancer populations.